911 results on '"Griffiths, Christopher E. M."'
Search Results
2. Skin health of community-living older people: a scoping review
3. Estimating the burden of vitiligo: a systematic review and modelling study
4. Factors Predicting Quality of Life Impairment in Adult Patients with Atopic Dermatitis: Results from a Patient Survey and Machine Learning Analysis
5. EGFR/MEK inhibitor therapy induces a distinct inflammatory hair follicle response that includes a collapse of immune privilege
6. Prevalence, incidence, mortality, and healthcare resource use for generalised pustular psoriasis, palmoplantar pustulosis, and plaque psoriasis in England: a population-based cohort study
7. Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure
8. Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis
9. Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study
10. Menopause induces changes to the stratum corneum ceramide profile, which are prevented by hormone replacement therapy
11. Prevalence of anxiety and depression symptoms among patients with psoriasis in Kabul, Afghanistan.
12. Exploring the Quality of Communication Between Patients with Psoriatic Arthritis and Physicians: Results of a Global Online Survey
13. National, regional, and worldwide epidemiology of psoriasis : systematic analysis and modelling study
14. The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
15. Implementing wellbeing in the management of psoriasis: An expert recommendation
16. Progress to Date in Advancing Stratified Medicine in Psoriasis
17. Author Correction: Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis
18. Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis
19. Remodelling of fibrillin-rich microfibrils by solar-simulated radiation: impact of skin ethnicity
20. Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
21. Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
22. Advocacy for a shared physician/patient approach for the management of acne, rosacea, seborrheic dermatitis and photodamage
23. Characteristics of 'super responders' and 'super nonresponders' to first biologic monotherapy for psoriasis: a nested case–control study.
24. Prevalence of multiple long-term conditions with psoriasis in England: A cohort study using the Clinical Practice Research Datalink.
25. Implementing well‐being in the management of psoriasis: An expert recommendation.
26. Risk of serious infection and infection mortality in patients with psoriasis: A nationwide cohort study using the Taiwan National Health Insurance claims database.
27. Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis.
28. Human Mast Cells Upregulate Cathepsin B, a Novel Marker of Itch in Psoriasis
29. Essential emergency skincare: a global health dermatology innovation for Myanmar and beyond
30. Behaviour and sun exposure in holidaymakers alters skin microbiota composition and diversity
31. Blood-based scoring systems for identifying significant liver fibrosis in patients with psoriasis
32. Prevalence of psoriasis and other autoimmune skin diseases in a recently contacted Amerindian community in the Auaris region, Yanomami territory, Brazil
33. Incidence and prevalence of generalized pustular psoriasis in multiethnic Johor Bahru, Malaysia: a population-based cohort study using routinely captured electronic health records in the Teleprimary Care (TPC®) clinical information system from 2010 to 2020
34. Improving skin health of community-dwelling older people: a scoping review protocol
35. Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody for the Treatment of Generalised Pustular Psoriasis: Results from the Phase 2 GALLOP Trial
36. Acrodermatitis continua of Hallopeau and generalised pustular psoriasis: Should they be the same or different entities?
37. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: A drug utilisation study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
38. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
39. A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial
40. Incidence and prevalence of generalized pustular psoriasis in multiethnic Johor Bahru, Malaysia: a population-based cohort study using routinely captured electronic health records in the Teleprimary Care (TPC®) clinical information system from 2010 to 2020
41. Photoaging in Caucasians
42. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis
43. Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis:a cohort study from BADBIR
44. Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study
45. Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Improvements in Quality of Life and Clinical Efficacy in Two Pivotal Phase 3 Trials
46. Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes
47. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
48. Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes
49. Migrant skin health – Perspectives from the Migrant Health Summit, Malta, 2022
50. Access to psoriasis treatment in Brazil and Chile: A cross-sectional multi-centre `Global Healthcare Study on Psoriasis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.